Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
1847 Goedeker (GOED)
PaxMedica (PXMD)
Vistas Media Acquisition (VMACU)
Yucaipa Acquisition (YAC.U)
Rackspace Technology, Inc. (RXT)
GO Acquisition (GOAC.U)
BigCommerce Holdings, Inc (BIGC)
Rocket Companies, Inc. (RKT)
Oak Street Health, Inc. (OSH)
Acutus Medical Inc (AFIB)
IBEX Holdings Limited (IBEX)
Checkmate Pharmaceuticals, Inc. (CMPI)
Freeline Therapeutics Holdings plc (FRLN)
Priced IPO
Fathom Holdings (FTHM)
Vital Farms, Inc. (VITL)
Vasta Platform Limited (VSTA)
AlloVir, Inc. (ALVR)
Li Auto Inc. (LI)
Vertex, Inc. (VERX)
iTeos Therapeutics, Inc. (ITOS)
Inozyme Pharma, Inc. (INZY)
Annexon, Inc. (ANNX)
Nurix Therapeutics, Inc. (NRIX)
Montrose Environmental Group, Inc. (MEG)
Skillful Craftsman Education Technology Ltd. (EDTK)
Jamf Holding Corp. (JAMF)
Renalytix AI plc (RNLX)
Berkeley Lights, Inc. (BLI)
Pandion Therapeutics, Inc. (PAND)
ALX Oncology Holdings Inc. (ALXO)
Trean Insurance Group, Inc. (TIG)
Relay Therapeutics, Inc. (RLAY)
GoHealth, Inc. (GOCO)
More companies

PaxMedica (PXMD)

Sector - Healthcare

IPO Profile

About company

They are an early clinical stage biopharmaceutical company focusing on the development of anti-purinergic therapies (or APT), for the treatment of neurodevelopmental disorders, including autism spectrum disorder (or ASD), and Fragile X syndrome tremor-ataxia (or FXTAS). Antipurinergic therapies target the excess production of purines in cells, which can offset homeostasis and result in an overproduction of cellular adenosine triphosphate (or ATP), the main energy molecule in all living cells. Their primary focus is currently on the development and testing of their lead program, PAX-101, an intravenous formulation of suramin, in the treatment of ASD and FXTAS. They are also focused on the treatment of Human African Trypanosomiasis (or HAT), where they are seeking to leverage suramin’s historical use in this indication, and data that they have exclusively licensed directly from certain academic or international government institutions to potentially accelerate PAX-101’s development in the U.S.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Howard J. Weisman Joseph Lucchese
Employees Founded
4 2018

Contacts

Address: 50 Tice Boulevard, Suite A26, Woodcliff Lake, NJ 07677, US

Telephone: (201) 645-4765

Web page: http://www.paxmedica.com

IPO information

Expected Date 7/27/2020
Status Week of
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $59.1
Revenues (MM) $0
Net Income (Loss) (MM) $-0.76

Voting

What do you think will happen with the PXMD share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 2.5
Shares Revised (MM) -
Expected offer amount (MM) $17
Realized offer amount(MM) -
Underwriters
The Benchmark Company
CO-Managers
-

Sector: Healthcare

Tweets about $PXMD

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats